Terms: = Endocrine gland cancer AND PR, PGR, progesterone receptor AND Treatment
768 results:
1. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract] [Full Text] [Related]
2. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
3. Mesonephric-like adenocarcinoma of the ovary.
Yang Y; Zhao M; Jia Q; Tang H; Xing T; Li Y; Tang B; Xu L; Wei W; Zheng H; Shi R; Xia B; Chen J
J Ovarian Res; 2024 Mar; 17(1):57. PubMed ID: 38444000
[TBL] [Abstract] [Full Text] [Related]
4. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
[TBL] [Abstract] [Full Text] [Related]
5. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
6. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Cristea MC; Stewart D; Synold T; Ruel N; Mortimer J; Wang E; Jung A; Wilczynski S; Konecny GE; Eng M; Kilpatrick L; Han E; Dellinger T; Hakim A; Lee S; Morgan RJ; Wakabayashi MT; Frankel PH
Gynecol Oncol; 2024 Mar; 182():124-131. PubMed ID: 38262235
[TBL] [Abstract] [Full Text] [Related]
7. Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.
Qin Y; Huang S; Tang J; Fan Y; Deng X; Guan P; Zhang Z; Wen Q; Li D
Front Immunol; 2023; 14():1329951. PubMed ID: 38235148
[TBL] [Abstract] [Full Text] [Related]
8. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
9. Combined Lanreotide Autogel and Temozolomide treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract] [Full Text] [Related]
10. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report.
Tong F; Sun Y; Zhu Y; Sha H; Ni J; Qi L; Gu Q; Zhu C; Xi W; Liu B; Kong W; Du J
Front Immunol; 2023; 14():1277810. PubMed ID: 38179049
[TBL] [Abstract] [Full Text] [Related]
11. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ
J Exp Clin Cancer Res; 2024 Jan; 43(1):4. PubMed ID: 38163893
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Significance of Multi-cancer Genome Profiling: Data from a Single Hospital in Japan.
Aoyama R; Nishikubo H; Kawabata K; Kanei S; Yamamoto Y; Nishimura S; Yashiro M
Cancer Genomics Proteomics; 2024; 21(1):79-87. PubMed ID: 38151295
[TBL] [Abstract] [Full Text] [Related]
13. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
14. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab treatment in Patients with Advanced Ovarian cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract] [Full Text] [Related]
15. The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death.
Koyanagi T; Saga Y; Takahashi Y; Tamura K; Yoshiba T; Takahashi S; Taneichi A; Takei Y; Mizukami H; Fujiwara H
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1934. PubMed ID: 38013666
[TBL] [Abstract] [Full Text] [Related]
16. Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic cancer Cells.
Che PP; Gregori A; Bergonzini C; Ali M; Mantini G; Schmidt T; Finamore F; Rodrigues SMF; Frampton AE; McDonnell LA; Danen EH; Slotman BJ; Sminia P; Giovannetti E
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1328-1343. PubMed ID: 37914140
[TBL] [Abstract] [Full Text] [Related]
17. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic cancer.
Horiguchi S; Matsumoto K; Morimoto K; Matsumi A; Terasawa H; Fujii Y; Yamazaki T; Tsutsumi K; Kato H
Acta Med Okayama; 2023 Oct; 77(5):517-525. PubMed ID: 37899263
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of pretreatment FDG PET-CT for short-term efficacy of radioactive iodine-125 seed implantation in patients with NSCLC.
Hu T; Shen J; Shao M; Feng X; Lu D; Ding E
Brachytherapy; 2023; 22(6):882-888. PubMed ID: 37758577
[TBL] [Abstract] [Full Text] [Related]
19. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line treatment for Metastatic Pancreatic cancer.
Wilbur HC; Durham JN; Lim SJ; Purtell K; Bever KM; Laheru DA; De Jesus-Acosta A; Azad NS; Wilt B; Diaz LA; Le DT; Wang H
Cancer Res Commun; 2023 Aug; 3(8):1672-1677. PubMed ID: 37645623
[TBL] [Abstract] [Full Text] [Related]
20. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?
Donisi G; Nappo G; Pacilli M; Capretti GL; Spaggiari P; Sollai M; Bozzarelli S; Zerbi A
Updates Surg; 2023 Sep; 75(6):1497-1508. PubMed ID: 37578734
[TBL] [Abstract] [Full Text] [Related]
[Next]